Dementia

APOE-targeted epigenome therapy for Alzheimer’s disease

Meta-analysis of the latest anti-amyloid immunotherapies: benefit vs risk

Blood-based biomarkers as surrogates of amyloid burden in preclinical Alzheimer’s disease

Promise of exosomal proteins as biomarkers in Alzheimer’s disease

Limitations of [18F]flortaucipir tau-PET imaging

First-in-human clinical trial of the anti-PD-L1 antibody, IBC-Ab002, in early AD

Lecanemab and what this means for the future treatment of Alzheimer’s disease

Speech biomarker for cognition: a novel marker for AD clinical trial screening

Ensuring the safety of epigenome therapies in the treatment of Alzheimer’s disease

Future direction for anti-amyloid immunotherapies

Next generation tau tracers: [18F]MK-6420 vs [18F]flortaucipir

Ongoing and future efforts in functional genomics in Alzheimer’s disease

Is amyloid load a valid surrogate endpoint for AD clinical trials?

What’s next for clinical trials in Alzheimer’s disease?

Precision medicine in Alzheimer’s treatment: genetics and co-pathologies

Astrocyte biomarkers associated with amyloid-β and tau pathologies